An Open-Label, Nonrandomized, Crossover Study to Evaluate the Potential Effect of Multiple Doses of Neratinib on the Pharmacokinetics of a Single Dose of Digoxin When Administered Orally to Healthy Adult Subjects.

Trial Profile

An Open-Label, Nonrandomized, Crossover Study to Evaluate the Potential Effect of Multiple Doses of Neratinib on the Pharmacokinetics of a Single Dose of Digoxin When Administered Orally to Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Digoxin; Neratinib
  • Indications Atrial fibrillation; Atrial flutter; Breast cancer; Heart failure; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Actual patient number is 27 according to ClinicalTrials.gov.
    • 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
    • 28 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top